{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', '6.2.', 'Exclusion Criteria', 'Participants will not be eligible for inclusion in this study if any of the following criteria', 'apply at screening (Week -4 and Week -2) and randomization (Day 1), unless', 'otherwise specified:', 'CKD Related Criteria', '1. Dialysis: On dialysis or clinical evidence of impending need to initiate dialysis', 'within 180 days after randomization (Day 1).', '2. Kidney Transplant: Planned living-related or living-unrelated kidney transplant', 'within 28 weeks after randomization (Day 1).', 'Anemia-Related Criteria', '3. Transferrin saturation (TSAT) <15% (Screening only)', '4. Ferritin <50 ng/mL (Screening only)', '5. rhEPO or rhEPO analogues: History of rhEPO or rhEPO analogue use within', 'the 8 weeks prior to screening and rhEPO use between screening and', 'randomization (Day 1).', '6. Transfusion: History of transfusion within the 8 weeks prior to screening and', 'transfusion between screening and randomization (Day 1).', '7. Aplasias: History of bone marrow aplasia or pure red cell aplasia (PRCA)', '8. Other causes of anemia: Megaloblastic emia(untreated pernicious anemia and', 'folate deficiency), thalassemia major, sickle cell disease or myelodysplastic', 'syndrome', '9. Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal,', 'or esophageal ulcer disease OR clinically significant GI bleeding VI 8 weeks prior', 'to screening through to randomization (Day 1)', 'Concomitant medication and other study treatment-related criteria', '10. Severe Allergic reaction: History of severe allergic or anaphylactic reactions or', 'hypersensitivity to excipients in the investigational product.', '11. Drugs and supplements: Use of strong inhibitor of CYP2C8 (e.g ,gemfibrozil)', 'or strong inducers of CYP2C8 (e.g., rifampin/rifampicin).', '12. Ferric Citrate: Ferric citrate use within 4 weeks prior to randomization (Day 1)', 'Prior Clinical Study Experience', '13. Other interventional study participation: Use of other investigational agent or', 'device prior to screening through to randomization (Day 1).', 'a. Note: at screening, this exclusion applies to use of the investigational', 'agent within 30 days or within five half lives (whichever is longer).', '14. Prior treatment with daprodustat: Any prior treatment with daprodustat for a', 'treatment duration of >30 days.', '40']['2016N298481_02', 'CONFIDENTIAL', '-', '205270', 'Cardiovascular Disease-Related Criteria (see also other cardiovascular exclusion', 'criteria #22)', '15. MI or acute coronary syndrome: within the 8 weeks prior to screening through', 'to randomization. (Day 1)', '16. Stroke or transient ischemic attack: within the 8 weeks prior to screening', 'through to randomization. (Day 1)', '17. Heart failure: Chronic Class IV heart failure, as defined by the New York Heart', 'Association (NYHA) functional classification system', '18. QTcB (Day 1): QTcB >500 msec or QTcB >530 msec in participants with bundle', 'branch block. There is no QTc exclusion for participants with a predominantly', 'paced rhythm.', 'Other Disease Related Criteria', '19. Liver Disease-Related Criteria:', 'Alanine transaminase (ALT) >2x upper limit of normal (ULN) at', 'screening (Week -4).', 'Bilirubin > 1.5xULN at screening (Week -4). NOTE: Isolated bilirubin', '>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin', '<35%.', 'Current unstable liver or biliary disease per investigator assessment,', 'generally defined by the presence of ascites, encephalopathy,', 'coagulopathy, hypoalbuminaemia, esophageal or gastric varices,', 'persistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease', '(including asymptomatic gallstones, chronic hepatitis B or C, or', \"Gilbert's syndrome) is acceptable if participant otherwise meets entry\", 'criteria.', '20. Malignancy: History of malignancy within the 2 years prior to screening through', 'to randomization (Day 1), or currently receiving treatment for cancer, or complex', 'kidney cyst (e.g. Bosniak Category II F, III or IV) > 3cm. Note: The only', 'exception is localized squamous cell or basal cell carcinoma of the skin that has', 'been definitively treated >8 weeks prior to screening.', 'Other Exclusion', '21. Other Conditions: Any other condition, clinical or laboratory abnormality, or', 'examination finding that the investigator considers would put the participant at', 'unacceptable risk, which may affect study compliance or prevent understanding', 'of the aims or investigational procedures or possible consequences of the study.', 'Other cardiovascular exclusion criteria', '22. Current uncontrolled hypertension: Current uncontrolled hypertension as', 'determined by the investigator', '41']\n\n###\n\n", "completion": "END"}